Disclosure Panels Details Page
Genetic/Familial High-Risk Assessment: Colorectal Panel - Disclosures as of 02/02/2021
|
Panel Member
(Spouse/Domestic Partner/Dependent) |
Clinical Research Support/Data Safety Monitoring Board | Scientific Advisory Boards, Consultant, or Expert Witness | Promotional Advisory Boards, Consultant, or Speakers Bureau | Employment/ Governing Board, Patent, Equity, or Royalty | Has Attended |
|---|---|---|---|---|---|
| Lisen Axell MS | None | None | None | None | ✔ |
| Marian Birkeland PhD | None | None | None | None | - |
| Carol Burke MD | cancer prevention pharmaceuticals Ferring Pharmaceuticals Janssen Pharmaceutica Products, LP |
Ferring Pharmaceuticals freenome inc SLA pharma |
Freenome inc SLA pharma |
None | ✔ |
| Mallory Campbell PhD | None | None | None | None | ✔ |
| Lee-May Chen MD | Clovis Oncology GSK Merck & Co., Inc. |
None | None | None | - |
| Daniel Chung MD | Iterative Scopes | Guardant | None | None | ✔ |
| Katherine Clayback MS, CGC | None | None | None | None | ✔ |
| Susan Dallas | None | None | None | None | - |
| Susan Darlow PhD | None | None | None | None | ✔ |
| Mary Dwyer MS | None | None | None | None | ✔ |
| Seth Felder MD | None | None | None | None | - |
| Olumide Gbolahan MD | None | AstraZeneca Pharmaceuticals LP Eisai Inc. Merck & Co., Inc. QED therapeutics |
None | None | - |
| Francis Giardiello MD, MBA | None | None | None | None | - |
| William Grady MD | Diacarta Janssen Pharmaceutica Products, LP Lucid Technologies Tempus |
Freenome Guardant Health SEngine |
None | None | - |
| Kristina Gregory MSN, RN | None | None | None | None | - |
| Samir Gupta MD | Epigenomics Freenome |
Cellmax Freenome Guardant |
None | None | ✔ |
| Michael Hall MD, MS | None | None | None | None | ✔ |
| Heather Hampel MS, LGC | National Cancer Institute | Genome Medical Invitae Genetics Promega |
None | None | ✔ |
| Rachel Hodan MS, CGC | None | None | None | None | ✔ |
| Gregory Idos MD, MS | Myriad Genetic Laboratories, Inc. | None | None | None | ✔ |
| Priyanka Kanth MD, MS, FACG | None | Provepharm | None | None | - |
| Bryson Katona MD, PhD | Epigenomics Freenome Guardant Immunovia Janssen Pharmaceutica Products, LP |
None | None | None | ✔ |
| Xavier Llor MD, PhD | None | None | None | None | - |
| Patrick Lynch MD, JD | Cancer Prevention Pharmaceutical SLA Pharma |
SLA Pharma | None | None | - |
| Lillias Maguire MD | None | None | None | None | - |
| Arnold Markowitz MD | None | None | None | None | ✔ |
| Sara Pirzadeh-Miller MS, CGC | None | None | None | None | ✔ |
| James Polson BSRT (R) (CT) (MR) | None | None | None | None | ✔ |
| Jewel Samadder MD | Cancer Prevention Pharmaceuticals Janssen Pharmaceutica Products, LP |
Cancer Prevention Pharmaceuticals Janssen Pharmaceutica Products, LP Recursion Pharmaceuticals |
None | None | - |
| David Shibata MD, FACS, FASCRS | None | None | None | None | - |
| Benjamin Swanson MD, PhD | None | None | None | None | ✔ |
| Brittany Szymaniak PhD, LCGC | None | "Technology-enhanced AcceleRation of Germline Evaluation for Therapy - The TARGET study" which has been funded by the Prostate Cancer Foundation. Clovis Oncology |
UroGPO | None | ✔ |
| Jennifer Weiss MD, MS | None | None | American College of Physicians Medscape |
None | ✔ |
| Georgia Wiesner MD | None | None | None | None | ✔ |
| Andrew Wolf MD | None | None | None | None | ✔ |
| Matthew Yurgelun MD | Janssen Pharmaceutica Products, LP | Janssen Pharmaceutica Products, LP UpToDate |
None | None | - |
| Mae Zakhour MD | None | None | None | None | ✔ |